Approved for use through 10/31/2002. OMB-0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Attorney Docket Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

Sheet

Complete if Known

Application Number 09/912,499

Filing Date July 26, 2001

First Named Inventor David Hung

Group Art Unit 3763

Examiner Name Unknown

005284.00096

(use as many sheets as necessary)

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title on Cite the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, No.1 number(s), publisher, city and/or country where published Papanicolaou et al, Exfoliative Cytology Of The Human Mammary Gland And Its Value In The Diagnosis Qu Cancer And Other Diseases Of The Breast, Cancer, Vol. 11, pp 377-409, 1956 Goodson WH & King EB, Chapter 4: Discharges and Secretions of the Nipple, The Breast: Comprehensive Management of Benign and Malignant Diseases, 2nd Ed., Bland & Kirby Eds. W.B. Saunders Col, Philadelphia PA, Vol. 2,, pp 51-74, 1998 King et al, Nipple Aspirate Cytology for the Study of Breast Cancer Precursors, Journal of the National Cancer Institute, Vol 71(6), pp 1115-21, 1983 Wrensch et al, Breast Cancer Incidence in Women with Abnormal Cytology in Nipple Aspirates of Breast Fluid, Am. J. Epidemiology, Vol. 135 (2), pp 130-141, 1992 Sauter et al, Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk, British Journal of Cancer, Vol. 76 (4), pp 494-501, 1997 Sartorius et al, Cytologic Evaluation of Breast Fluid in the Detection of Breast Disease, Journal of the National Cancer Institute, Vol. 59 (4), pp 1073-80, 1977 Love and Barsky, Breast-duct endoscopy to study stages of cancerous breast disease, Lancet, Vol. 348(9033), pp 997-9, 1996 Makita et al, Duct endoscopy and endoscopic biopsy in the evlauation of nipple discharge, Breast Cancer Res Treat Vol. 18, pp 179-188, 1991 Okazaki et al, Fiberoptic Ductoscopy of the Breast: A New Diagnostic Procedure for Ni[pple Discharge, , Jpn J. Clin. Oncol. Vol. 21, pp 188-193, 1991 Petrakis, Studies on the Epidemiology and Natural History of Benign Breast Disease and Breast Cancer Using Nipple Aspirate Fluid, Cancer Epidemiology. Biomarker Prev., Vol. 2, pp 3-10, 1993 Petrakis, Psysiologic, biochemical, and cytologic aspects of nipple aspirate fluid, Breast Cancer Res. Treat, Vol. 8, pp 7-19, 1986

| Examiner Signature | Mathru | is I Man | Date Considered | 12/16 | 102. |
|-----------------------|--------------|----------|--------------------|-------|------|
| | 10 100 40 00 | | 7-07 | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2009. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 09/912,499 Filing Date July 26, 2001 First Named Inventor **David Hung** Group Art Unit 3763 **Examiner Name** Unknown **Attorney Docket Number** 005284.00096

(use as many sheets as necessary) heet 2 of

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) Aitle of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-isside g number(s), publisher, city and/or country where published. Cite Examiner No.1 wrensch et al, Breast Cancer Res Treat, Factors associated with obtaining nipple aspirate fluid: Analysis of 1428 Initials * Wrensch et al, Breast Fluid Cholesterol and Cholesterol B-Epoxide Concentrations in Women with Benign Breast Disease, Cancer Res., Vol. 49,pp 2168-2174, 1989 Mechanical Engineering, Vol. 118 (10), pp 65-68, 1996 King et al, Analytic Studies of Foam Cells From Breast Cancer Precursors, Cytometry, Vol. 5, pp 124-130, 1984 King et al, Cellular Composition of the Nipple Aspirate Specimen of Breast Fluid, A.J.C.P., Vol. 64, pp 739-748, King et al, Cellular Composition of the Nipple Aspirate Specimen of Breast Fluid, A.J.C.P., Vol. 64, pp 728-738, Masood et al, The Missing Link: A "Pap Smear" For Early Breast Cancer Detection and Prevention, The Breast Journal, Vol. 5, pp 1-2, 1999 Sartorius et al, Cytologic Evaluation of Breast Fluid in the Detection of Breast Disease, Journal of National Cancer, Vol. 59, pp 1073-1080, 1977 Sauter et al, Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk, British J. Cancer, Vol. 76(4), pp 494-501, 1997 Wrensch et al, Breast Cancer Incidence in Women with Abnormal Cytology in Nipple Aspirates of Breast Fluid, Amer J. Epid., Vol. 135, pp 130-141, 1992 Frykberg and Masood Copeland EM 3d Bland Kl., (Ductal carcinoma in situ of the breast) Surgery, Gynecology & Obstetrics, Vol. 177 (4), pp 425-40, 1993

| Examiner Signature | Date Manuser Considered | 12/16/02. |
|-----------------------|-------------------------|-----------|
| | | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.